Paradigm Biocapital Advisors LP Prothena Corp Public LTD CO Transaction History

Paradigm Biocapital Advisors LP

  • $2.77 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$52.05 - $65.0 $8.37 Million - $10.5 Million
-160,826 Reduced 68.2%
75,000 $4.52 Million
Q3 2022

Nov 14, 2022
BUY
$25.16 - $60.63 $5.93 Million - $14.3 Million
235,826 New
235,826 $14.3 Million
Q2 2022

Aug 15, 2022
SELL
$22.73 - $39.98 $6.09 Million - $10.7 Million
-267,946 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$30.27 - $49.22 $8.11 Million - $13.2 Million
267,946 New
267,946 $9.8 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email